Viewing Study NCT05055232

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 9:46 PM
Ignite Modification Date: 2026-04-02 @ 6:10 AM
Study NCT ID: NCT05055232
Status: COMPLETED
Last Update Posted: 2025-07-24
First Post: 2021-09-14
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: A Phase I Study of XZP-3621 in Chinese Patients With ALK or ROS1 Rearrangement Non-small Cell Lung Cancer
Sponsor: Xuanzhu Biopharmaceutical Co., Ltd.
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None ROS1 Rearrangement Non-small Cell Lung Cancer View
None ALK Rearrangement Non-small Cell Lung Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None XZP-3621 View
None Dose escalation and expansion View